Copyright
©2006 Baishideng Publishing Group Co.
World J Gastroenterol. Apr 21, 2006; 12(15): 2417-2422
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2417
Published online Apr 21, 2006. doi: 10.3748/wjg.v12.i15.2417
Figure 1 Median HBV DNA titers during PEG-IFN-α 2b therapy and during follow-up.
Figure 2 Median ALT values, expressed as multiples of ULN, during PEG-IFN-α 2b therapy and during follow-up.
Figure 3 Changes in median inflammation and fibrosis scores according to end of treatment virological response.
- Citation: Vassiliadis T, Patsiaoura K, Tziomalos K, Gkiourtzis T, Giouleme O, Grammatikos N, Rizopoulou D, Nikolaidis N, Katsinelos P, Orfanou-Koumerkeridou E, Eugenidis N. Pegylated IFN-α 2b added to ongoing lamivudine therapy in patients with lamivudine-resistant chronic hepatitis B. World J Gastroenterol 2006; 12(15): 2417-2422
- URL: https://www.wjgnet.com/1007-9327/full/v12/i15/2417.htm
- DOI: https://dx.doi.org/10.3748/wjg.v12.i15.2417